PMID- 28830840
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 182
DP  - 2018 Feb
TI  - Binge-eating disorder: Clinical and therapeutic advances.
PG  - 15-27
LID - S0163-7258(17)30212-7 [pii]
LID - 10.1016/j.pharmthera.2017.08.002 [doi]
AB  - Binge-eating disorder (BED) is the most prevalent eating disorder with estimates 
      of 2-5% of the general adult population. Nonetheless, its pathophysiology is 
      poorly understood. Furthermore, there exist few therapeutic options for its 
      effective treatment. Here we review the current state of binge-eating 
      neurobiology and pharmacology, drawing from clinical therapeutic, neuroimaging, 
      cognitive, human genetic and animal model studies. These studies, which are still 
      in their infancy, indicate that while there are many gaps in our knowledge, 
      several key neural substrates appear to underpin binge-eating and may be 
      conserved between human and animals. This observation suggests that behavioral 
      intermediate phenotypes or endophenotypes relevant to BED may be modeled in 
      animals, facilitating the identification and testing of novel pharmacological 
      targets. The development of novel, safe and effective pharmacological therapies 
      for the treatment of BED will enhance the ability of clinicians to provide 
      optimal care for people with BED.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hutson, Peter H
AU  - Hutson PH
AD  - Department of Neurobiology, CNS Discovery, Teva Pharmaceuticals, West Chester, 
      PA, USA. Electronic address: peter.hutson@tevapharm.com.
FAU - Balodis, Iris M
AU  - Balodis IM
AD  - Peter Boris Centre for Addiction Research, Department of Psychiatry and 
      Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
FAU - Potenza, Marc N
AU  - Potenza MN
AD  - Department of Psychiatry, Child Study Center, Yale University School of Medicine, 
      New Haven, CT, USA; Department of Neuroscience, Yale University School of 
      Medicine, New Haven, CT, USA; National Center on Addiction and Substance Abuse, 
      USA; Connecticut Mental Health Center, New Haven, CT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170819
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
SB  - IM
MH  - Animals
MH  - Binge-Eating Disorder/diagnostic imaging/*drug therapy/psychology
MH  - Brain/diagnostic imaging/*drug effects
MH  - Disease Models, Animal
MH  - Humans
OTO - NOTNLM
OT  - Binge-eating disorder
OT  - Compulsivity
OT  - Impulsivity
OT  - Neurobiology
OT  - Pharmacotherapy
OT  - Reward
EDAT- 2017/08/24 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/08/24 06:00
PHST- 2017/08/24 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/08/24 06:00 [entrez]
AID - S0163-7258(17)30212-7 [pii]
AID - 10.1016/j.pharmthera.2017.08.002 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2018 Feb;182:15-27. doi: 10.1016/j.pharmthera.2017.08.002. Epub 
      2017 Aug 19.